Cantel Medical Corp. (CMD) Hit 12-Month High on May, 16

May 16, 2018 - By Nellie Rakes

Cantel Medical Corp. (NYSE:CMD) having $127.67 price per share and $139.16 price target broke into 52 week high. It was announced on May, 16 by The company has $5.33B MC. The valuation of NYSE:CMD can change by $479.34M if our $139.16 price target is broke into.

CMD is touching $127.67 during the last trading session, after increased 2.23%.Currently Cantel Medical Corp. is uptrending after 41.41% change in last May 16, 2017. CMD has 161,870 shares volume. CMD outperformed the S&P500 by 29.86%.

On May, 31 WallStreet awaited Cantel Medical Corp. (NYSE:CMD)’s earnings report, Zacks reports. EPS of $0.60 is 17.65 % up from 2017’s $0.51 EPS. If the current EPS of $0.60 is accurate, CMD’s profit could be $25.03M. 1.69 % EPS growth is what analysts predict. $0.59 EPS was revealed for last quarter.

There’s a significant Cantel Medical Corp. (NYSE:CMD) news released by It’s an item titled: “Jim Cramer Weighs In On Align Technology, Berkshire Hathaway, Symantec And More” on May 15, 2018.

Cantel Medical Corp. provides infection prevention services and products for the healthcare market worldwide.The firm is worth $5.33 billion. The firm operates through four divisions: Endoscopy, Water Purification and Filtration, Healthcare Disposables, and Dialysis.59.22 is the P/E ratio. The Endoscopy segment offers automated endoscope reprocessing systems; detergents; leak testing and manual cleaning products; storage cabinets; transport systems; mobile medical carts; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid and flexible endoscopes, and other instrumentation; cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures; and technical maintenance services.

Cantel Medical Corp. (NYSE:CMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: